REMARKS

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. ASZD-P01-707 from which the undersigned is authorized to draw.

Dated: November 29, 2004

Respectfully submitted,

David P. Halstead

Registration No.: 44,735 ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

Application No.: Not Yet Assigned Docket No.: ASZD-P01-707

Abstract

Modified Release Pharmaceutical Formulation

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R₁ represents C?=2#191 alkyl substituted by one or more fluoro substituents; R₂ represents hydrogen, hydroxyl, methoxy or ethoxy; and n represent 0, 1 or 2; or a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain ita-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder.